Portola Pharmaceuticals Announces Dosing of First Patient

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings

SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. ® (NASDAQ: PTLA ), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies.

Portola recently completed a Phase 1 study of cerdulatinib, which identified the maximum tolerated dose. Pharmacokinetic and pharmacodynamic outcomes data from the Phase 1 study will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2016, which is taking place from June 3-7 in Chicago. Final results of the Phase 1 study, as well as data from two other cerdulatinib studies, will be presented in poster and e-poster sessions at the European Hematology Association (EHA) 21 st Annual Congress, which is taking place from June 9-12 in Copenhagen.

The cerdulatinib ASCO abstract is available at abstracts.asco.org and the EHA abstracts are available at http://bit.ly/1U852D2 . Details regarding the poster and e-poster presentations, which will include additional data not available in the abstracts, follow.

ASCO Annual Meeting 2016

  • Abstract Title (abstract #7557/poster board #113): Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies -- Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing
  • Presenting Author : Paul A. Hamlin, M.D., medical oncologist, Memorial Sloan Kettering Cancer Center
  • Poster Session Title : Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
  • Poster Presentation Date and Time : Monday, June 6, 8:00-11:30 a.m. Central Time
  • Location : McCormick Place, Hall A

EHA 21 st Congress

  • Abstract Title (abstract #LB2252): Phase 1 final results and Phase 2a dose selection for cerdulatinib (PRT062070), a dual Syk/JAK inhibitor in patients with relapsed/refractory B-cell malignancies
  • Session Title : Chronic lymphocytic leukemia and related disorders -- Clinical
  • E-poster Presentation Date and Time : Friday, June 10, 9:30 a.m.-Saturday, June 11, 7 p.m. CEST
  • E-Poster Location : Bella Center, Hall H  
  • Abstract Title (abstract #E1017): Combined SYK and JAK inhibition by cerdulatinib induces apoptosis in CLL and overcomes resistance to ibrutinib
  • Session Title : Chronic lymphocytic leukemia and related disorders -- Biology
  • E-poster Presentation Date and Time : Friday, June 10, 9:30 a.m.-Saturday, June 11, 7 p.m. CEST
  • Location : Bella Center, Hall H  
  • Abstract Title (abstract #P590): The SYK/JAK inhibitor cerdulatinib shows promising in vitro activity in chronic lymphocytic leukemia
  • Session Title : Genomic complexity in CLL
  • Poster Presentation Date and Time : Saturday, June 11, 5:30-7:00 p.m. CEST
  • Location: Poster Area, Hall H

About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma. 

Investor Contact: Ana Kapor Portola Pharmaceuticals ir@portola.com Media Contact: Julie Normart W2O Group jnormart@w2ogroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 64

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 96

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 48

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 222

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 104

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 98

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 136

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 30

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 126

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Scaling New Heights: S&P 500's Path to 6,500

Updated Category News Views 260

Market Rally Highlights The financial markets witnessed an impressive surge recently, with significant recoveries noted in leading indexes. The S&P 500, a crucial gauge for large-cap stocks, notably rose by 10.6% during the second quarter of the year. Many factors contributed to this remarkable increase, underscoring investor confidence despite some ongoing challenges in...

Continue Reading
Pultruded Spar Cap Market Growth: Forecasting US$ 2.1 Billion

Updated Category News Views 194

Insights into the Pultruded Spar Cap Market and Future Growth The Pultruded Spar Cap Market is on the cusp of significant expansion, with projections suggesting a robust annual growth rate of 16.7% from 2024 through 2030. Industry analyses indicate that this favorable trend could lead to a market size of US$ 2.1 billion by the end of the projection period. This report is...

Continue Reading
Irritable Bowel Syndrome Treatment Growth Projections 2033

Updated Category News Views 107

Irritable Bowel Syndrome: An Overview Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that can significantly affect a person's quality of life, leading to a range of uncomfortable symptoms such as abdominal discomfort, bloating, and irregular bowel movements. With various subtypes like IBS with Diarrhea (IBS-D) and IBS with Constipation (IBS-C), it...

Continue Reading
Anoto Group Reports Second Quarter Results 2024

Updated Category News Views 242

Overview of the Interim Report for 2024 The interim report covering January to June 2024 provides important insights into Anoto Group AB's operations and financial health. Anoto Group continues to be a leader in technology, particularly in optical recognition and digital writing. This report emphasizes key financial metrics and the company's strategic initiatives in a...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 276

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading